Veracyte SVP McGuire receives stock grants

McGuire Annie reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

McGuire Annie reported acquisition or exercise transactions in this Form 4 filing.

VERACYTE, INC. reported that SVP and General Counsel Annie McGuire received two equity grants of common stock on March 6, 2026, both at no cash cost to her. Following these awards, she directly holds 153,912 shares.

The first grant of 32,892 restricted stock units vests 25% on March 2, 2027 and then 1/16 each quarter, subject to her continued employment on each vesting date. The second grant of 26,314 restricted stock units vests in full on the first anniversary of the grant, also contingent on continued employment.

Insider Trade Summary

Grant/Award: 59,206 shares

Grant/Award 2 txns

Insider McGuire Annie

Role SVP, General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	32,892	$0.00	$0.00
Grant/Award	Common Stock	26,314	$0.00	$0.00

Holdings After Transaction: Common Stock — 153,912 shares (Direct)

Footnotes (2)

1. F1. Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.
2. F2. Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Veracyte (VCYT) disclose in Annie McGuire’s latest Form 4?

Veracyte reported that SVP and General Counsel Annie McGuire received two stock-based awards on March 6, 2026. These are restricted stock unit grants that vest over time and increased her direct holdings to 153,912 common shares after the reported transactions.

How many Veracyte shares were granted to Annie McGuire in this Form 4?

Annie McGuire received one grant of 32,892 restricted stock units and a second grant of 26,314 restricted stock units. Both awards were reported as acquisitions of common stock at a price of $0.00 per share, reflecting equity compensation rather than open-market purchases.

What are the vesting terms of Annie McGuire’s new Veracyte equity awards?

One restricted stock unit award vests 25% on March 2, 2027, with the remaining 75% vesting in sixteen equal quarterly installments. The second award vests in full on the first anniversary of the March 6, 2026 grant date, subject to her continued employment.

Were Annie McGuire’s Veracyte transactions open-market stock purchases?

No. The Form 4 classifies both transactions under code A as grants or awards. The reported price per share is $0.00, indicating these were equity compensation awards of restricted stock units rather than open-market purchases of Veracyte common stock by Annie McGuire.

How many Veracyte shares does Annie McGuire own after these grants?

After the reported March 6, 2026 awards, Annie McGuire directly owns 153,912 shares of Veracyte common stock. This total reflects her position following the second grant as disclosed, giving investors a snapshot of her updated direct equity stake in the company.

What conditions apply to vesting of Annie McGuire’s Veracyte restricted stock units?

Both restricted stock unit awards are subject to her continuing employment on each vesting date. If she remains employed through the schedule, units will vest either quarterly after March 2, 2027 or in full on the first anniversary of the March 6, 2026 grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 05:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McGuire Annie

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A(1)		32,892	A	$0	127,598	D
Common Stock	03/06/2026		A(2)		26,314	A	$0	153,912	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

2. Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.